<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01313819</url>
  </required_header>
  <id_info>
    <org_study_id>H-1012-044-344</org_study_id>
    <nct_id>NCT01313819</nct_id>
  </id_info>
  <brief_title>The Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy</brief_title>
  <official_title>A Double Blind, Placebo-controlled Study for the Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tp determine the effect of IV amantadine on dopaminergic-drug-resistant freezing of
      gait(FOG)in patients with Parkinson`s disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Freezing of gait (FOG) is one of the most disabling symptoms of Parkinson`s disease.

           We experienced that severe FOG was markedly improved by IV amantadine in the patients
           who had Parkinson`s disease. But IV drug may have placebo effect. Therefore, We designed
           double blind, placebo controlled study to know whether IV amantadine is effective in the
           patient with dopaminergic-drug-resistant freezing of gait(FOG).

        2. Cross over study design

             -  Compare the change of FOGQ(freezing of gait questionaire) score from the baseline
                to IV amantadine and placebo drug

             -  randomized assigned order of amantadine and placebo drug.

             -  investigator of FOG: blinded to the order of drugs

             -  each patient has IV drug for 2 days for each drug
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of FOGQ score</measure>
    <time_frame>2 days for each drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>UPDRS and HY stage</measure>
    <time_frame>2 days for each drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effect</measure>
    <time_frame>2 days, 2 weeks after discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global impression</measure>
    <time_frame>2 days, 2 weeks after discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4*10m walk test</measure>
    <time_frame>2 days for each drug</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Parkinson`s Disease</condition>
  <condition>Freezing of Gait</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Give IV amantadine first then IV placebo(normal saline) drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Give IV placebo drug first then IV amantadine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj</intervention_name>
    <description>IV amantadine at 200 mg in 500 cm3 of saline solution or normal saline 500 cm3 given over a 3-h period, twice a day for 2 days along with the pre-existing dopaminergic and non-dopaminergic medication</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  age: 30-80 years

          -  idiopathic Parkinson's disease

          -  The patient must be taking optimised levodopa/DDI therapy (based on investigator's
             judgement) during OPD observation period, though the patient have FOG-Q score ≥ 10
             points even though On-state.

        Exclusion Criteria:

          -  &quot;Off&quot; freezing:The patient has improved FOG in &quot;On&quot; state

          -  clinically significant or unstable medical or surgical condition

          -  The patient has Parkinson plus like MSA, PSP, and PPFG, and secondary parkinsonism
             like NPH, vascular parkinsonism, postencephalitic parkinsonism, CO poisoning.

          -  history of seizure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beom S Jeon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beom S Jeon, MD, PhD</last_name>
    <phone>82-2-2072-2876</phone>
    <email>brain@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beom S Jeon, MD, PhD</last_name>
      <phone>82-2-2072-2876</phone>
      <email>brain@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Beom S Jeon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Young Eun Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Giladi N, Kao R, Fahn S. Freezing phenomenon in patients with parkinsonian syndromes. Mov Disord. 1997 May;12(3):302-5.</citation>
    <PMID>9159723</PMID>
  </reference>
  <reference>
    <citation>Giladi N. Medical treatment of freezing of gait. Mov Disord. 2008;23 Suppl 2:S482-8. doi: 10.1002/mds.21914. Review. Erratum in: Mov Disord. 2008 Aug 15;23(11):1639-40.</citation>
    <PMID>18668620</PMID>
  </reference>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2011</study_first_submitted>
  <study_first_submitted_qc>March 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2011</study_first_posted>
  <last_update_submitted>November 9, 2011</last_update_submitted>
  <last_update_submitted_qc>November 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>BS Jeon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Freezing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amantadine</mesh_term>
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Dopamine Agents</mesh_term>
    <mesh_term>Dopamine Agonists</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 3, 2012</submitted>
    <returned>February 2, 2012</returned>
    <submitted>May 5, 2017</submitted>
    <returned>November 2, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

